Clinical Trial
A Phase 1 Multicenter Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Cancer Type
Gene & Cellular Immunotherapy
Protocol Number
202603056
Principal Investigator
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Protocol Interventions
Drug: SOC+ BSB-2002
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.